62 results about "Isolated population" patented technology

The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same.

Methods of treating patients for conditions such as breast augmentation, soft tissue defects, and urinary incontinence, are described. The methods include removing adipose tissue from a patient, processing a portion of the adipose tissue to obtain a substantially isolated population of regenerative cells, mixing the regenerative cells with another portion of adipose tissue to form a composition, and administering the composition to the patient from which the adipose tissue was removed.

This invention also provides a purified or isolated population of ADSCs that can differentiate into a cell of the leiomyogenic lineage, e.g., smooth muscle or skeletal muscle. In yet another aspect, the population additionally can be differentiated into a lineage selected from the group consisting of osteogenic, adipogenic, chondrogenic, myogenic and neuronal. This invention further provides a composition comprising a substantially homogeneous expanded population of smooth muscle cells. This invention provides a composition comprising a substantially homogeneous expanded population of skeletal muscle cells. Also provided herein is an isolated composition comprising a purified adipose-derived stem cell (ADSC) or progeny of said ADSC and an effective amount of laminin or heparin, effective to induce leiomyogenic differentiation. Diagnositic and therapeutic uses for these compositions are provided herein.

This invention is a method of minimizing the variation of cell growth and production through homogeneous cell line development. To be more specific, it is the method of isolating and proliferating single cell clone from the procambium to promote the stability of the plant-derived biologically active substances production by solving the problems of decrease in cell growth and the productivity during the long term culture.

An isolated population of cells is provided. The isolated population of cells comprising at least one secretor cell capable of secreting a molecule and at least one sensor cell capable of producing a detectable signal upon being exposed to the molecule.

This invention also provides a purified or isolated population of ADSCs that can differentiate into a cell of the leiomyogenic lineage, e.g., smooth muscle or skeletal muscle. In yet another aspect, the population additionally can be differentiated into a lineage selected from the group consisting of osteogenic, adipogenic, chondrogenic, myogenic and neuronal. This invention further provides a composition comprising a substantially homogeneous expanded population of smooth muscle cells. This invention provides a composition comprising a substantially homogeneous expanded population of skeletal muscle cells. Also provided herein is an isolated composition comprising a purified adipose-derived stem cell (ADSC) or progeny of said ADSC and an effective amount of laminin or heparin, effective to induce leiomyogenic differentiation. Diagnositic and therapeutic uses for these compositions are provided herein.

This invention provides an isolated population of polynucleotides comprising or corresponding to at least one polynucleotide shown in Table 1 and their respective complements. It also provides a polynucleotide encoding a ligand or antibody or engineered protein that binds to a cell surface protein of an antigen presenting cell and wherein the polynucleotide comprises or corresponds to a polynucleotide shown in Table 1 or its complement. The invention further provides a polynucleotide that encodes a transcription factor and wherein the polynucleotide comprises or corresponds to a polynucleotide shown in Table 1 or its complement.

Provided are compositions and methods for enhancing immune responses to an antigen. The compositions contain an isolated population of CD8+T cells and an inhibitor of mammalian target of rapamycin (mTOR). The method for obtaining an enhanced immune response to an antigen in an individual entails administering to the individual the antigen and an inhibitor of mammalian target of rapamycin (mTOR). CD8+T cells may also be used for adoptive cell transfer (ACT) therapy.

The present invention provides an isolated population of adult hematopoietic stem cells (HSC) derived from embryonic stem cells (ESC) induced to differentiate in vitro by culturing ESCs in a medium with stem cell factor, interleukin (IL)-3, and IL-6. HSC of immunophenotype c-kit+ or c-kit+ / CD45+ from this population are isolated and injected either intra bone marrow or intravenously into myeloablated recipient individuals. This method allows for the establishment of banks of allogeneic ESC-derived adult stem cells for treatments of autoimmune diseases, immune deficiencies and induction of immunotolerance during organ transplantation. These allogeneic ESC-derived adult hematopoietic stem cells (HSC) may be used in reconstituting bone marrow, without the development of teratomas or graft versus host disease, despite crossing histocompatibility barriers. Additionally, allogeneic ESC-derived HSC can be used to prevent the development of autoimmune diseases or organ rejection during transplantation.

The invention provides for isolated population of pulp marrow similar cells (DPMSCs) and methods for isolating and using these cells. The population of DPMSCs are highly homogenous for CD1O, CD29, CD13, CD44, CD49a, CD49d, CD59, CD73, CDw90, CD105, Oct-4 Isoform A and B, Nanog, Sox-2, and SSEA-4.

The present invention provides an isolated population of perineurium derived adult stem cells and cells derived thereof. The cells of the invention are obtained from the perineurium of peripheral nerves and demonstrate the ability to expand and differentiate in response to BMP2. The invention also provides methods of using the cells of the invention, for example in methods to promote neuroregeneration and bone formation.

The present invention relates to an isolated population of osteoblastic cells, which are characterized by cell surface markers N-cad<+> and CD45<->, with such osteoblastic cells used in vitro to promote and support growth of HSCs. Additionally, the present invention relates to vectors, which include a Bmpr1a nucleic acid sequence, recombination sites, and a plasmid, wherein the vectors can be used to promote an increase in the HSC population in vivo.

A method is provided for the isolation of endothelial progenitor cells from a source of progenitor cells by isolating a population of lineage-negative cells and further isolating CD34+ cells from the lineage-negative population by fluorescence-activated cell sorting. Isolated populations of endothelial progenitor cells and therapeutic compositions containing CD34+ cells for the induction of blood vessels, induction of angiogenic responses in surrounding blood vessels and the chemotaxis of inflammatory cells are also provided.

A method of treating a disease in a subject in need thereof is disclosed. The method comprising: (a) transplanting a non-syngeneic cell or tissue graft to the subject; and (b) administering to the subject a therapeutically effective amount of an isolated population of cells comprising non-graft versus host (GVHD) inducing anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance-inducing cells and capable of homing to the lymph nodes following transplantation, and further wherein the cells are either: (i) non-syngeneic with both the subject and the graft; or (ii) non-syngeneic with the graft and syngeneic with the subject, thereby treating the subject.

This invention discloses isolated populations of human cancer stem cells. Methods for characterizing, isolating and culturing human cancer stem cells are also disclosed. Uses for human cancer stem cells are provided.

An isolated population of cells comprising non-GVHD inducing anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype is provided. The cells being tolerance-inducing cells and capable of homing to the lymph nodes following transplantation. Methods of generating same, use of same and methods of treatment are also provided.

Disclosed herein are compositions and methods for the generation of insulin positive β cells, for example by exposing Pdx+ pancreatic progenitor cells to one or more compounds, and compositions and kits comprising isolated populations of insulin positive cells.

The invention is directed to T cells and other cells that express chimeric NK-p30 receptors (“chimeric NKp30 T cells”), methods of making and using chimeric NKp30 T cells, and methods of using these chimeric NKp30 T cells, isolated populations thereof, and compositions comprising the same. In another aspect, said chimeric NKp30 T cells are further designed to express a functional non-TCR receptor. The disclosure also pertains to methods of making said chimeric NKp30 T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said chimeric NKp30 T cells, populations thereof, or compositions comprising the same.

Methods are provided for the isolation, characterization and propogation of germline cells stem cells from fetal and adult mammals. Additionally, isolated populations of germline cells having different phenotypes are disclosed wherein the subpopulations are capable of forming long-term cultures of multipotent or pluripotent cells or are capable of differentiating into mature germline cells and repopulating a sterile reproductive organ. The multipotent or pluripotent germline cells are also suitable for differentiation into tissue-specific somatic cells for therapeutic purposes.

A method of generating an isolated population of cells comprising anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance-inducing cells and / or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) contacting peripheral blood mononuclear cells (PBMC) with a third party antigen or antigens in the presence of IL-21 so as to allow enrichment of antigen reactive cells; and (b) culturing the cells resulting from step (a) in the presence of IL-21, IL-15 and IL-7 in an antigen free environment so as to allow proliferation of cells comprising the central memory T-lymphocyte (Tcm) phenotype.

An isolated population of cells comprising non-GVHD inducing anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype is provided. The cells being tolerance-inducing cells and capable of homing to the lymph nodes following transplantation. Methods of generating same, use of same and methods of treatment are also provided.

This invention is a method of minimizing the variation of cell growth and production through homogeneous cell line development. To be more specific, it is the method of isolating and proliferating single cell clone from cambium to promote the stability of the plant-derived biologically active substances production by solving the problems of decrease in cell growth and the productivity during the long term culture.

The present invention provides methods of transdifferentiation of somatic cells, for example, directly converting a somatic cell of a first cell type, e.g., a fibroblast into a somatic cell of a second cell type, are described herein. In particular, the present invention generally relates to methods for converting a somatic cell, e.g., a fibroblast into a motor neuron, e.g., an induced motor neuron (iMN) with characteristics of a typical motor neuron. The present invention also relates to an isolated population comprising induced motor neurons (iMNs), compositions and their use in the treatment of motor neuron diseases such as ALS and SMA. In particular, the present invention relates to direct conversion of a somatic cell to an induced motor neuron (iMN) having motor neuron characteristics by increasing the protein expression of at least three motor-neuron inducing (MN-inducing) factors selected from Lhx3, Ascl1, Brn2, Myt1l, Isl1, Hb9, Ngn2 or NeuroD1 in a somatic cell, e.g., a fibroblast to convert the fibroblast to an induced motor neuron (iMN) which exhibits at least two characteristics of an endogenous motor neuron.

This invention is a method of minimizing the variation of cell growth and production through homogeneous cell line development. To be more specific, it is the method of isolating and proliferating single cell clone from procambium to promote the stability of the plant-derived biologically active substances production by solving the problems of decrease in cell growth and the productivity during the long term culture.

Methods of culturing sebocyte cells, isolated populations of sebocytes, and methods of using the cultured sebocyte cells for screening compounds that inhibit or activate lipogenesis are provided.

Disclosed are methods of isolating and using a population of FOXP3+ regulatory T cells in a variety of preventative and therapeutic approaches to autoimmune diseases, graft-versus-host disease and transplant rejection.

Isolated populations of leukemic stem cells are provided. The cells are useful for experimental evaluation, and as a source of lineage and cell specific products, and as targets for the discovery of factors or molecules that can affect them. Detection of leukemic stem cells is useful in predicting disease progression, relapse, and development of drug resistance. Proliferation of LSC may be inhibited through interfering with activation of the beatenin pathway. Methods are provided for the clinical staging of pre-leukemia and leukemias by differential analysis of hematologic samples for the distribution of one or more hematopoietic stem or progenitor cell subsets.

The invention discloses a molecular marker of rice purple leaf sheath gene PSH1(t) linkage, and an acquired method and an application thereof, which belong to the field of molecular genetics. The rice non purple leaf sheath variety fragrant japonica 9407 and the purple leaf sheath variety R151 and the F2 which is obtained by hybridization are extracted with isolated population individual DNA. The two parents receives the PCR product polymorphism screening by utilizing 360 pairs of SSR molecular markers, then the screening of the molecular markers of purple leaf sheath gene linkage is carried out sequentially to a F2 mixing pool with purple leaf sheath DNA, a F2 mixing pool without purple leaf sheath DNA and each of the individuals of a F2 population, and the molecular genetic map of the purple leaf sheath gene PSH1(t) is constructed on the first chromosome. The selection efficiency of purple leaf sheath rice is greatly improved through the molecular markers of the major genes of purple leaf sheaths to test whether purple leaf sheath variety R151 and derived varieties (lines) thereof contain the genes of the purple leaf sheaths. The invention is specialized in the screening of the rice purple leaf sheath genes, and is used for the study of cloning the purple leaf sheath gene PSH1 (t).

The invention is directed to methods for generating pancreatic progenitor cells, insulin producing cells or endoderm cells using embryonic stem cells and induced pluripotent stem cells. The present invention also relates to an isolated population comprising pancreatic progenitor cells or a insulin-producing cells, compositions and their use in the treatment of diabetes